Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Breast Neoplasms

Triple Negative Breast Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma, Transitional Cell

Endometrial Neoplasms

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Neoplasms

Uterine Diseases

Breast Diseases

Skin Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Transitional Cell Carcinoma

PRO1107 monotherapy in escalating doses in Part A and at the two recommended phase 2 doses in Part B

PRO1107

ProfoundBio Trial Support

This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, PK, and antitumor activity of PRO1107 in patients with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.

This is a Phase 1/2 study of PRO1107, a PTK7 targeted antibody-drug conjugate, to evaluate the safety, tolerability, PK, and antitumor activity of PRO1107 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, triple negative breast cancer, non-small cell lung cancer, gastroesophageal cancer, and urothelial cancer. This study consists of 2 parts, Part A: Dose Escalation and Part B: Dose Expansion.

Part A may evaluate up to 7 dose levels of PRO1107 on Day 1 of a 21 day cycle by IV infusion.

Part B will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, PD and activity data from Part A in up to 4 different cohorts of up to 40 patients per cohort.

Patients will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.

PRO1107 in Patients With Advanced Solid Tumors

A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors

Measure of anti-drug antibodies of PRO1107 in serum

Type, incidence, severity, seriousness, and relatedness of adverse events

Type, incidence, and severity of laboratory abnormalities

Patients who achieve partial or complete response per RECIST v1.1 criteria

Patients who achieve stable disease, partial or complete response per RECIST v1.1 criteria

Time from start of treatment to first documented disease progression or death

Time from the first documentation of an objective tumor response (CR or PR) to the first documented tumor progression or death

Measure of PRO1107 area under the concentration-time curve (AUC) in plasma.

Measure of the maximum concentration (Cmax) of PRO1107 in plasma.

Measure of the time to maximum concentration (Tmax) of PRO1107 in plasma.

Measure of apparent terminal half-life (t1/2) of PRO1107 in plasma.

Measure of the trough concentration (Ctrough) of PRO1107 in plasma.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
PRO1107 in Patients With Advanced Solid Tumors	NCT06171789	Endometrial Can... Ovarian Cancer Triple Negative... GastroEsophagea... Non-small Cell ... Urothelial Carc...	PRO1107	18 Years -	ProfoundBio US Co.
PRO1107 in Patients With Advanced Solid Tumors	NCT06171789	Endometrial Can... Ovarian Cancer Triple Negative... GastroEsophagea... Non-small Cell ... Urothelial Carc...	PRO1107	18 Years -	ProfoundBio US Co.

Spots Global Cancer Trial Database for pro1107

Every month we try and update this database with for pro1107 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for pro1107

Every month we try and update this database with for pro1107 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for pro1107 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.